Lilly dustbins edivoxetine depression indication

Share this article:

Eli Lilly's Phase III test of edivoxetine for major depressive disorder is a fail. The company announced Thursday that the drug failed to surpass placebo when paired with a selective serotonin reuptake inhibitor (SSRI).

The company is dustbinning this indication, but ISI Group analyst Mark Schoenebaum wrote in his news assessment that Lilly may put the drug into the roster of possible ADHD therapies. Regardless, Schoenebaum writes Lilly's news won't upset Wall Street's opinion of the company. “Investors haven't exactly been optimistic that these Phase III trials would work, so today's news is not entirely surprising,” he writes.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Allergan reported to seek out Salix deal

The Wall Street Journal says the deal would add "another layer of intrigue" to the Allergan-Valeant hostilities.

India's Marck gets FDA Warning Letter

Inspectors of Marck Biosciences found an array of problems during a October-November 2013 inspection, including mold near a sterile area that was so bad "the room had 'partially caved in.'"

DOJ closes Brilinta investigation

AstraZeneca announced the end of the investigation Tuesday.